ROCKVILLE, Md., Aug. 27, 2009 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF) (“the Company”), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced it entered into securities purchase agreements with investors to raise gross proceeds of approximately $420,000, before placement agent’s fees and other offering expenses, in a registered direct offering. This represents the second and final tranche to the financing previously announced on August 12, 2009, which raised an initial approximate $1,050,000.
